Paper Details

  1. Home
  2. Paper Details

A novel c-Met/TRK inhibitor 1D228 efficiently inhibits tumor growth by targeting angiogenesis and tumor cell proliferation.

Author: AnBaijiao, FanYangyang, HuJinhui, LiWei, LiXingshu, LiuJiadai, NieHaoran, NieWenyan, RenYuanyuan, TianGeng, WangMengxuan, WeiMengna, YangChunhua, YaoHan, ZhangChuanchuan, ZhangYin, ZhaoYaxuan

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study developed a new tyrosine kinase inhibitor, 1D228, that targets both c-Met and TRK, two proteins that promote tumor growth. 1D228 showed better anti-tumor activity in laboratory and animal studies than other drugs that target these proteins. The study suggests that 1D228 may be a promising new treatment for cancer patients with abnormal expressions of c-Met or NTRK.
Paper Details　
Original Abstract of the Article :
Multiple tumors are synergistically promoted by c-Met and TRK, and blocking their cross-signalling pathway may give better effects. In this study, we developed a tyrosine kinase inhibitor 1D228, which exhibited excellent anti-tumor activity by targeting c-Met and TRK. Models in vitro, 1D228 showed a...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10636171/

データ提供：米国国立医学図書館（NLM）

1D228: A Novel c-Met/TRK Inhibitor for Cancer Treatment

Cancer, a complex and challenging disease, often involves multiple pathways that contribute to tumor growth. This study explores the potential of a novel tyrosine kinase inhibitor, 1D228, to target both c-Met and TRK pathways, which play a role in promoting cancer growth.

Researchers investigated the effects of 1D228 in laboratory and animal models, observing its ability to inhibit tumor growth by targeting both c-Met and TRK pathways. Their findings suggest that 1D228 holds promise as a potential treatment option for various types of cancer, offering a novel approach to targeting multiple cancer-promoting pathways. This research opens new avenues for exploring more effective and targeted cancer treatments.

A Multi-Target Approach to Cancer Therapy

This research showcases the potential of multi-target approaches to cancer therapy, focusing on inhibiting multiple pathways that contribute to tumor growth. This strategy could lead to more effective treatments with fewer side effects, improving outcomes for cancer patients.

Fighting Cancer

Imagine a vast desert where a small but tenacious plant is trying to survive. Just as that plant faces various challenges, cancer cells must overcome numerous obstacles to grow and spread. This research explores new ways to combat cancer, targeting multiple pathways to disrupt the growth and spread of tumors, giving hope for a future with better treatment outcomes.

Dr. Camel's Conclusion

This study offers a glimpse into the future of cancer treatment, highlighting the potential of multi-target approaches to combat this devastating disease. The development of 1D228, a novel tyrosine kinase inhibitor that targets both c-Met and TRK pathways, represents a significant step forward in the fight against cancer, offering hope for more effective and personalized treatment strategies.

Date :
  1. Date Completed 2023-11-13
  2. Date Revised 2023-11-13
Further Info :

Pubmed ID

37945598

DOI: Digital Object Identifier

PMC10636171

Related Literature

Article Analysis
・Effects of tepotinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.